INREEDI, a pioneering R&D enterprise specializing in low-temperature radiofrequency (RF) medical devices, has recently announced the completion of a Pre-A funding round that raised tens of millions of Renminbi (RMB). Led by NRL Capital, the raised funds will be strategically allocated to three core areas: accelerating domestic and international market promotion for flagship product, the BeaShape Radiofrequency Therapy Device; advancing clinical research on new therapeutic indications; and supporting R&D for the company’s subsequent product pipelines.
Core Team & Product Vision: Merging “Professional Efficacy” with “Consumer Experience”
INREEDI’s team is composed of industry specialists from top global medical enterprises, with an average of over 15 years of experience. The company also established in-depth collaborations with internationally leading scientists in the field of RF technology. Its core mission is to deliver RF treatment solutions that combine “professional-grade efficacy” with “consumer-grade experience” – INREEDI’s flagship product, the BeaShape Radiofrequency System embodies this philosophy.
This financing round not only injects strong momentum into INREEDI’s growth but also signals the market’s full recognition of its approach to solving the “pain points” in the medical aesthetics (med-aesthetic) industry. Domestic innovative med-aesthetic devices, represented by BeaShape, guided by the principle of “technology as the foundation, experience as the enabler,” are now opening a new chapter of market breakthroughs, backed by their solid clinical value and outstanding user experience.
Technological Breakthrough: Rewriting Industry Standards with Gentle, Safe, and Efficient RF Therapy
BeaShape Radiofrequency System stands out with two proprietary technologies: INREEDI’s Continuous Pulse Width Modulation (CPWM) technology and Software-Defined Waveform System. Its unique energy output strategy operates like “gentle and steady streams providing sustained, deep hydration” – abandoning the traditional high-power pulsed heating method of conventional devices, it delivers mild yet continuous deep tissue heating.
Crucially, this ensures safety and comfort as priority, while efficiently accumulating the effective thermal dose required for collagen regeneration, without the need for cooling system intervention throughout the procedure.
The multi-center trials data led by the Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, has demonstrated outstanding and encourating results. Key metrics, including significant anti-wrinkle efficacy and exceptional comfort feedback (with a mean Visual Analog Scale (VAS) score of just 0.17), are expected to be officially published in authoritative academic journals in the near future. This publication will provide detailed and rigorous academic evidence for the system’s performance.
Investor Perspective: NRL Capital Highlights INREEDI‘s Global Competitiveness
A representative from NRL Capital emphasized the firm’s confidence in INREEDI, stating: “We continue to focus on innovative breakthroughs in the medical technology sector. INREEDI’s team possesses profound technical accumulation and an international R&D perspective, paired with precise insights into the pain points of the consumer healthcare market – these collectively form the company’s core competitive advantages. The BeaShape System’s excellent clinical data, particularly in its exceptional comfort and high efficacy, establishes strong differentiated competitiveness within its products category, highlighting global leadership and scarcity. We firmly believe that INREEDI has the potential to become a benchmark enterprise in the upgrading wave of China’s medical devices, and even an important player in the global RF medical device market. We maintain unwavering confidence in its capacity to generate long-term value for the industry.”
About INREEDI
INREEDI is a medical device R&D enterprise focused on low-temperature RF technology. Built on its independently developed technology platform, the company has successfully launched a range of RF energy devices and obtained multiple Class III medical device registration certificates (a top-tier certification for medical devices in China).
Its unique 45℃ Low-Temperature RF Cutting and Coagulation Technology has demonstrated superior precision and safety in delicate surgical procedures such as plastic surgery, earning wide recognition from medical experts. Leveraging in-depth in vivo animal studies and clinical practice, INREEDI’s R&D team – which includes talents with international backgrounds – has also overcome the limitations of traditional RF technology to develop a 50W monopolar high-efficiency RF technology specifically for med-aesthetic anti-aging applications.
In terms of commercialization, INREEDI is accelerating the construction of its market promotion channals: it has established deep partnerships with leading med-aesthetic distributors across key regions in China. Meanwhile, the company is also actively building a professional market promotion and technical support team to lay a solid foundation for future product market penetration.
About NRL Capital
NRL Capital is an investment and fund management platform that leverages first-class domestic and international industrial resources and long-term capital. It integrates three capabilities – fund of funds, direct investment, and private equity secondary share investment – and operates with a dual-wheel drive of onshore RMB and offshore USD. It focuses on sectors such as medical and health, semiconductors and intelligent manufacturing, new energy and carbon neutrality, and consumer technology.
About Probe Capital
Probe Capital, founded in 2017, is a boutique investment bank focused on biomedicine and cutting-edge technology. Since its establishment, it has completed double-digit private equity financing and M&A transactions annually, with a cumulative transaction volume of tens of billions of RMB. Headquartered in Shanghai, the company also has offices in Beijing, Hangzhou, and Suzhou. Probe Capital served as the exclusive financial advisor for INREEDI’s this round of financing.
BradyKnows Celebrates INREEDI’s Successful Financing Round as a Long-Term Strategic Partner
Since INREEDI’s establishment, BradyKnows has played an integral role in shaping and defining its technical roadmap. We have assisted INREEDI in conducting robust in vivo animal experiments, facilitated rigorous multi-center clinical trials, and provided comprehensive support across product pipeline development, team building, and financing resource. Having accompanied INREEDI throughout its growth journey, BradyKnows has helped the enterprise advance from technical validation to product implementation, culminating in its current strong capabilities of independent advancement. As an early supporter and strategic partner, we are delighted to witness the successful closing of this latest financing round.
BradyKnows remains committed to its mission: “To introduce innovative and life-improving medical and biotechnology products to Chinese patients.” We continue to focus on promoting medical innovations with clinical value and an international vision within the Chinese market, persistently contributing to the advancement of the healthcare industry through dedicated collaborative efforts.
